Kathy Hibbs Sells 6,250 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $8.68, for a total value of $54,250.00. Following the transaction, the director directly owned 103,242 shares in the company, valued at $896,140.56. This represents a 5.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Stock Performance

SOPH traded down $0.12 during trading hours on Wednesday, hitting $8.53. The stock had a trading volume of 232,020 shares, compared to its average volume of 241,759. The company’s fifty day simple moving average is $6.33 and its 200 day simple moving average is $5.37. SOPHiA GENETICS SA has a 1 year low of $3.10 and a 1 year high of $8.85. The stock has a market cap of $715.58 million, a PE ratio of -7.42 and a beta of 0.96. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. Equities analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently made changes to their positions in the business. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS in the first quarter worth $50,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS during the third quarter valued at about $49,000. Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the fourth quarter valued at about $49,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS in the fourth quarter worth about $54,000. Finally, XTX Topco Ltd purchased a new position in shares of SOPHiA GENETICS in the fourth quarter worth about $55,000. Institutional investors own 31.59% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on SOPH. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright raised their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, BTIG Research lifted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.